155 related articles for article (PubMed ID: 34123305)
1. Coordinating bioorthogonal reactions with two tumor-microenvironment-responsive nanovehicles for spatiotemporally controlled prodrug activation.
Zuo L; Ding J; Li C; Lin F; Chen PR; Wang P; Lu G; Zhang J; Huang LL; Xie HY
Chem Sci; 2020 Jan; 11(8):2155-2160. PubMed ID: 34123305
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Therapeutic Effect of Liposomal Doxorubicin
Kannaka K; Sano K; Munekane M; Yamasaki T; Hagimori M; Mukai T
Mol Pharm; 2022 May; 19(5):1400-1409. PubMed ID: 35404619
[TBL] [Abstract][Full Text] [Related]
3. Bioorthogonal micellar nanoreactors for prodrug cancer therapy using an inverse-electron-demand Diels-Alder reaction.
Suehiro F; Fujii S; Nishimura T
Chem Commun (Camb); 2022 Jun; 58(50):7026-7029. PubMed ID: 35642953
[TBL] [Abstract][Full Text] [Related]
4. Intracellular fluorogenic supramolecular assemblies for self-reporting bioorthogonal prodrug activation.
Zhao Y; Yao Q; Chen J; Zhang R; Song J; Gao Y
Biomater Sci; 2022 Sep; 10(19):5662-5668. PubMed ID: 35996984
[TBL] [Abstract][Full Text] [Related]
5. A tumor-specific ROS self-supply enhanced cascade-responsive prodrug activation nanosystem for amplified chemotherapy against multidrug-resistant tumors.
Wang J; Zhang H; Lv J; Zheng Y; Li M; Yang G; Wei X; Li N; Huang H; Li T; Qin X; Li S; Wu C; Zhang W; Liu Y; Yang H
Acta Biomater; 2023 Jul; 164():522-537. PubMed ID: 37072069
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy.
Huang J; Yao Z; Li B; Ping Y
J Control Release; 2023 Sep; 361():270-279. PubMed ID: 37541594
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the inverse electron demand Diels-Alder reaction in rats using a scandium-44-labelled tetrazine for pretargeted PET imaging.
Edem PE; Sinnes JP; Pektor S; Bausbacher N; Rossin R; Yazdani A; Miederer M; Kjær A; Valliant JF; Robillard MS; Rösch F; Herth MM
EJNMMI Res; 2019 May; 9(1):49. PubMed ID: 31140047
[TBL] [Abstract][Full Text] [Related]
8. A Synergistic Chemoimmunotherapy System Leveraging PD-L1 Blocking and Bioorthogonal Prodrug Activation.
Wang K; Jiang M; Li T; Liu Y; Zong Q; Xu Q; Ullah I; Chen Y; Xue W; Yuan Y
Adv Mater; 2024 May; ():e2402322. PubMed ID: 38718226
[TBL] [Abstract][Full Text] [Related]
9. A Dual-Mechanism Targeted Bioorthogonal Prodrug Therapy.
Yao Q; Lin F; Lu C; Zhang R; Xu H; Hu X; Wu Z; Gao Y; Chen PR
Bioconjug Chem; 2023 Dec; 34(12):2255-2262. PubMed ID: 37955377
[TBL] [Abstract][Full Text] [Related]
10. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
11. pH/ROS dual-responsive supramolecular polypeptide prodrug nanomedicine based on host-guest recognition for cancer therapy.
Ding Y; Wang C; Ma Y; Zhu L; Lu B; Wang Y; Wang J; Chen T; Dong CM; Yao Y
Acta Biomater; 2022 Apr; 143():381-391. PubMed ID: 35272024
[TBL] [Abstract][Full Text] [Related]
12. Inverse Electron Demand Diels-Alder Reactions in the Liposomal Membrane Accelerates Release of the Encapsulated Drugs.
Kannaka K; Sano K; Nakahara H; Munekane M; Hagimori M; Yamasaki T; Mukai T
Langmuir; 2020 Sep; 36(36):10750-10755. PubMed ID: 32830502
[TBL] [Abstract][Full Text] [Related]
13. ROS triggered cleavage of thioketal moiety to dissociate prodrug nanoparticles for chemotherapy.
Pan Q; Deng X; Gao W; Chang J; Pu Y; He B
Colloids Surf B Biointerfaces; 2020 Oct; 194():111223. PubMed ID: 32615519
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional Polymeric Prodrug with Simultaneous Conjugating Camptothecin and Doxorubicin for pH/Reduction Dual-Responsive Drug Delivery.
Dong S; Sun Y; Liu J; Li L; He J; Zhang M; Ni P
ACS Appl Mater Interfaces; 2019 Mar; 11(9):8740-8748. PubMed ID: 30693750
[TBL] [Abstract][Full Text] [Related]
15. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
16. Protein-Gated Upconversion Nanoparticle-Embedded Mesoporous Silica Nanovehicles via Diselenide Linkages for Drug Release Tracking in Real Time and Tumor Chemotherapy.
Yan H; Dong J; Huang X; Du X
ACS Appl Mater Interfaces; 2021 Jun; 13(24):29070-29082. PubMed ID: 34101411
[TBL] [Abstract][Full Text] [Related]
17.
Dong Y; Du P; Liu P
Int J Pharm; 2020 Oct; 588():119723. PubMed ID: 32755688
[TBL] [Abstract][Full Text] [Related]
18. IEDDA: An Attractive Bioorthogonal Reaction for Biomedical Applications.
Handula M; Chen KT; Seimbille Y
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361793
[TBL] [Abstract][Full Text] [Related]
19. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
[TBL] [Abstract][Full Text] [Related]
20. Cascade In Situ Self-Assembly and Bioorthogonal Reaction Enable the Enrichment of Photosensitizers and Carbonic Anhydrase Inhibitors for Pretargeted Cancer Theranostics.
Wen X; Zeng W; Zhang J; Liu Y; Miao Y; Liu S; Yang Y; Xu JJ; Ye D
Angew Chem Int Ed Engl; 2024 Jan; 63(4):e202314039. PubMed ID: 38055211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
